ALT — Altimmune, Inc.

Summary of Altimmune, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: $27.4 million for 2025, or $0.27 per share, compared to a net loss of $23.2 million, or $0.33 per share in 2024.
• R&D Expenses: $18.4 million in Q4 2025, down from $19.8 million in Q4 2024, primarily due to the conclusion of the Phase IIb trial.
• G&A Expenses: Increased to $10.5 million in Q4 2025 from $5.1 million in Q4 2024, attributed to executive transition costs and increased professional fees.
• Cash Position: Approximately $274 million at year-end 2025, with a pro forma cash position of about $340 million post-January capital raises, providing an operational runway into 2028.

2. Strategic Updates and Business Highlights

• PEMB Development: Focused on liver diseases, particularly NASH, with promising results from the Phase IIb MATCH study showing early NASH resolution and antifibrotic activity.
• FDA Breakthrough Therapy Designation: Received for PEMB in NASH, indicating potential for substantial improvement over existing therapies.
• Phase III Trial Preparation: Finalizing protocol and operational plans for a pivotal Phase III trial expected to start in 2026, with a target enrollment of approximately 1,800 patients.
• Market Research Insights: Identified unmet needs among NASH patients, particularly in tolerability and weight loss, positioning PEMB as a potential solution.

3. Forward Guidance and Outlook

• Phase III Trial Initiation: Expected to commence in 2026, with ongoing preparations and alignment with regulatory agencies.
• Top-line Data from AUD Trial: Anticipated in Q3 2026, with plans to assess the impact of PEMB on alcohol use and liver health.
• Long-term Value Creation: Commitment to advancing PEMB and addressing significant unmet needs in liver diseases, aiming for a strong market entry.

4. Bad News, Challenges, or Points of Concern

• Increased G&A Expenses: Significant rise due to executive transition costs may impact short-term financial stability.
• Regulatory Risks: While aligned with the FDA on trial design, there remains uncertainty regarding the acceptance of non-invasive tests (NITs) as registrational endpoints.
• Competitive Pressures: The evolving landscape of NASH therapies poses challenges, particularly from other dual agonists and therapies that may address similar patient needs.
• Enrollment Challenges: The ALD trial may face difficulties due to the severity of the population, potentially impacting timelines for data readouts.

5. Notable Q&A Insights

• FDA Discussions: Clarified that the FDA did not indicate flexibility on using NITs as primary endpoints at this stage, maintaining a focus on biopsy-driven endpoints.
• Enrollment Strategy: Plans to accept patients who have failed other therapies (e.g., semaglutide) in the Phase III trial to address unmet needs.
• Muscle Preservation Focus: Emphasis on the importance of lean mass preservation in the elderly population, with ongoing discussions on how to best assess this in clinical trials.
• Competitive Landscape: Management is closely monitoring competitors and believes PEMB's unique dual mechanism and favorable tolerability profile will differentiate it in the market.

This summary encapsulates the key points discussed during the earnings call, providing a clear overview of Altimmune's financial health, strategic direction, and market positioning as they prepare for significant clinical milestones ahead.